Zontivity discontinued?

Zontivity is the brand name for vorapaxar, a PAR-1 antagonist antiplatelet.

- Is it discontinued? There isn’t a clear, universal “discontinued” status I can confirm without your country. In the U.S., vorapaxar (Zontivity) has not been withdrawn from the market, but its use is limited because of significant bleeding risk. It is contraindicated in patients with a history of stroke, transient ischemic attack (TIA), or intracranial hemorrhage (ICH), and in those with active bleeding. It’s generally used only in select patients with prior myocardial infarction (MI) or peripheral artery disease (PAD) who are not at high risk of bleeding, in addition to aspirin and/or clopidogrel.

- Why you might be hearing “discontinued”: some markets have faced temporary supply issues or market withdrawal decisions by the company, which can be mistaken for a full global discontinuation. Regulatory status can also change over time.

What I can do for you:
- If you tell me your country, I can check the current regulatory/market status for Zontivity there.
- If you or someone you know is taking Zontivity, don’t stop the medicine without talking to a prescriber. I can explain the typical dosing, contraindications, and what to watch for, or help you prepare questions for your pharmacist or clinician.
- I can also suggest alternatives if the drug is not available in your area or if bleeding risk is a concern.

Would you like me to look up the status for a specific country, or share more details about your situation?